Top

Published in:

01-09-2018 | Clinical Trial Report

A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib

Authors: Lixia Ju, Mingquan Han, Jinmei Su, Chunyan Wu, Zhengwei Dong

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2018

Abstract

It is widely known that ROS1 rearrangement mostly occurs in the adenocarcinoma subtype of non-small-cell lung cancer. Patients with squamous cell carcinoma harboring ROS1 rearrangement are extremely rare. This is a case report of a squamous cell carcinoma patient with ROS1 rearrangement. An 84-year-old Chinese woman with a about 6.6 cm mass in the right middle lobe and right pleural effusion, enlarged mediastinal and hilar lymph nodes was diagnosed with stage IIIB lung squamous cell carcinoma harboring ROS1 rearrangement is highly sensitive to crizotinib in the first treatment setting. This is the first time to report lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib. We hope that oncologists will notice this phenomenon and it will help the lung squamous cell carcinoma patient to get longer overall survival time.

Bergethon K, Shaw AT, Ou SH et al (2012) ROS1rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863–870CrossRefPubMedPubMedCentral

Go H, Kim DW, Kim D et al (2013) Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 8(11):1445–1450CrossRefPubMed

Zhao W, Choi YL, Song JY et al (2016) ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer 94:22–27CrossRefPubMed

Wang R, Zhang Y, Pan Y et al (2015) Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget 6(33):34300–34308PubMedPubMedCentral

Matsumura Y, Umemura S, Ishii G et al (2015) Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma. J Cancer Res Clin Oncol 141(12):2159–2170CrossRefPubMedPubMedCentral

Penault-Llorca F, Tixier L, Perrot L, Cayre A (2016) Strategy for molecular testing in pulmonary carcinoma. Ann Pathol 36(1):73–79CrossRefPubMed

Schwab R, Petak I, Kollar M et al (2014) Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 83(1):109–111CrossRefPubMed

Kenmotsu H, Serizawa M, Koh Y et al (2014) Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. BMC Cancer 14:786CrossRefPubMedPubMedCentral

Mazières J, Zalcman G, Crinò L et al (2015) Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33:992–999CrossRefPubMed

10.

Moro-Sibilot D, Faivre L, Zalcman G et al (2015) Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial. J Clin Oncol 33:8065a

11.

Pfizer Inc. (2014) EU Xalkori (crizotinib) summary of product characteristics. http://www.ema.europa.eu/docs/enGB/document library/EPAR-ProductInformation/human/002489/WC500134759.pdf. Accessed 23 Apr 2014

12.

Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394 (and supplemental material) CrossRefPubMed

13.

Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703CrossRefPubMedPubMedCentral

14.

Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011–1019CrossRefPubMedPubMedCentral

15.

Kim D-W, Ahn M-J, Shi Y et al (2012) Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Poster presented at the 48th annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, June 1–5

Title: A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
Authors: Lixia Ju
Mingquan Han
Jinmei Su
Chunyan Wu
Zhengwei Dong
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3660-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors

Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation

A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat

A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer